In the present study, we aimed to assess the impact of RNA editing in thyroid cancer and to identify de novo cancer-related RNA editing sites using next generation sequencing in an ADAR1-knockdown cellular model. This evidence concerns the gene ADAR and thyroid gland carcinoma.